Breathing Better: How Personalized Care and Technology Are Changing COPD and Asthma By: Dr. Emma Lin Co-Founder, Pulmonary & Sleep Medicine Physician www.readyo2.com I'm Dr. Emma Lin, a lung and sleep specialist. I'm also a co-founder of Readyo2, and we help COPD and asthma people breathe easier. I regularly see patients and combine medical training and technology for optimum results. Beyond Medicines Medications help, but are not enough. Pulmonary rehab changes lives. Exercise strengthens breathing muscles. Techniques help loosen up mucus. Correct oxygen use prevents complications. Breathing Skills That Help - Diaphragmatic breathing: breathing with the abdomen. - Pursed-lip breathing: slow exhalation through pursed lips. - Airway clearance devices help some patients move mucus. Personalized Care Every patient is unique. I refer back to blood tests, lung scans, and history to classify asthma or COPD type, phenotyping. Phenotyping assists with treatment, rehab, oxygen therapy, or novel medication like biologics. Smarter Oxygen Use Standard oxygen flows at a steady rate. Most of our patients need an adjustable amount during exercise or at bedtime. With Readyo2, we individualize oxygen delivery with real-time titration. It's always just right, never too much or too little. Biologics and Precision Medicine Biologics keep immune messages like IL-5 or IgE from being sent in asthma. Steroid use reduces, severe symptoms are managed, and quality of life improves. Biologics for COPD are emerging and are promising for selected individuals. Barriers I See Cost, insurance authorizations, distance from rehab, and limited technical skills may hinder treatment. I overcome these with home programs, education, and individualized plans. Role of Primary Care Family doctors often detect lung problems first. Simple tests of breathing, oxygen saturation tests, and labs aid in identifying at-risk patients. Early patient referral to rehab or a pulmonologist works best. The Next 5 Years I am also looking forward to more COPD biologics, home rehabilitation with daily digital coaching, AI continuous monitoring of oxygen and symptoms, and wearables with daily lung monitoring. With Readyo2, oxygen therapy becomes safe, personal, and effective. My Takeaway Everyone is an individual. My job is to figure out what works, rehab, lung skills of breathing, biologics, or customized oxygen. Lung treatment is becoming specific, connected, and individualized.
Innovations in managing Chronic Obstructive Pulmonary Disease (COPD) and asthma are shifting towards a more holistic approach, moving beyond traditional medications. Key developments include non-pharmacological techniques such as pursed-lip and diaphragmatic breathing to enhance lung function. Additionally, pulmonary rehabilitation programs combine exercise, education, and self-management strategies, significantly improving patient's quality of life and exercise capacity.
Beyond pharmacotherapy, the biggest innovations are pulmonary rehabilitation including tele-rehab and home-based models, structured breathing retraining, and digital adherence tools like smart inhalers and remote monitoring that surface inhaler technique and use patterns. These approaches consistently improve exercise capacity, symptoms, and quality of life, and can extend rehab to patients who can't attend in-person programs. Physicians increasingly titrate oxygen to targets rather than maintain fixed flows, typically aiming for SpO2 ~88-92% in hypercapnia-prone COPD to avoid oxygen-induced CO2 retention. To match this activity, exertional testing or closed-loop titration is used. Early trials of automated or activity-adjusted oxygen show better functional capacity than fixed doses in some users, but real-world outcome data are still emerging. Regarding biologics and precision medicine in asthma, biologics matched to phenotype such as anti-IgE, anti-IL-5/5R, anti-IL-4R, anti-TSLP, etc., are standard for severe disease when biomarkers or clinical features align. In COPD, dupilumab became the first FDA-approved biologic for patients with eosinophilic or type-2 inflammation and is shown to reduce exacerbations in addition to maximal inhaled therapy. Importantly, this formalizes an inflammatory endotype within COPD. The main barriers that asthma and COPD patients face are cost, access due to limited rehab slots, coverage variability for digital tools or biologics, adherence, and infrastructure including training and reimbursement for tele-rehab. Evidence shows that smart inhalers are promising for increasing adherence and technique for patients, but payer adoption and definitive outcomes remain uneven. To mediate these barriers, primary care providers can prioritize lung function, provide vaccinations, refer patients early for pulmonary rehab, phenotype severe asthma and COPD to guide biologic referral, simplify treatments to single-inhaler regimens, and use brief oxygen-titration walk tests for exertional desaturation. Within the next 5 years, we expect to see scaled tele-rehab, closed-loop oxygen delivery, broader digital phenotyping with wearables and smart inhalers, endobronchial interventions for selected COPD hyperinflation, and expanded COPD biologics for defined inflammatory endotypes. Together, these physician interventions and advancements within the near future emphasize precision and personal respiratory medicine for optimal healthcare.